Financial Performance - The company's operating revenue for Q1 2023 was ¥42,418,265.20, a decrease of 32.86% compared to the same period last year[5] - The net profit attributable to shareholders was ¥7,716,721.48, down 61.92% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥5,374,407.65, reflecting a decline of 72.57%[5] - Total revenue for Q1 2023 was ¥42,418,265.20, a decrease of 32.8% compared to ¥63,179,209.56 in Q1 2022[20] - Operating profit for Q1 2023 was ¥7,823,729.78, down 66.7% from ¥23,452,801.43 in Q1 2022[21] - Net profit for Q1 2023 was ¥7,716,721.48, a decline of 61.9% compared to ¥20,263,118.79 in Q1 2022[21] - Total comprehensive income for Q1 2023 was ¥7,692,372.68, a decrease of 62.0% from ¥20,255,766.17 in Q1 2022[22] - Basic earnings per share were ¥0.02, down 65.73% year-on-year[6] - Basic earnings per share for Q1 2023 was ¥0.02, down from ¥0.05 in Q1 2022[22] Cash Flow and Liquidity - The net cash flow from operating activities increased by 97.80% to ¥18,585,769.41, primarily due to the collection of receivables[6] - Cash flow from operating activities for Q1 2023 was ¥18,585,769.41, an increase of 97.5% compared to ¥9,396,461.26 in Q1 2022[25] - The net cash flow from financing activities was -$99,558.00, a decrease from -$190,392.00 in the previous period, indicating improved cash management[26] - The net increase in cash and cash equivalents was -$313,354,291.53, compared to -$222,102,490.77 in the prior year, reflecting a significant cash outflow[26] - The beginning balance of cash and cash equivalents was $763,148,303.68, up from $511,651,941.84 year-over-year, showing a strong starting position[26] - The ending balance of cash and cash equivalents was $449,794,012.15, a decrease from $289,549,451.07 in the previous period, indicating a decline in liquidity[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,328,874,706.25, a slight decrease of 0.26% from the end of the previous year[6] - Total assets decreased slightly to ¥1,328,874,706.25 from ¥1,332,333,946.07, a decrease of about 0.3%[19] - Total liabilities decreased to ¥143,898,463.87 from ¥155,050,076.37, a reduction of approximately 7.2%[18] - The company’s equity attributable to shareholders increased to ¥1,184,976,242.38 from ¥1,177,283,869.70, an increase of about 0.7%[19] - The company reported a total current assets of ¥950,917,454.71, slightly down from ¥953,710,436.33[17] - The company’s non-current assets totaled ¥377,957,251.54, a minor decrease from ¥378,623,509.74[17] Research and Development - Research and development expenses totaled ¥10,885,029.09, a decrease of 41.50% compared to the previous year[6] - Research and development expenses decreased to ¥10,885,029.09 in Q1 2023 from ¥18,605,791.17 in Q1 2022, representing a reduction of 41.7%[20] - The company did not achieve revenue recognition for R&D technology transfer during the reporting period, resulting in a 100% year-on-year decline in related income[8] Market and Competition - The company faced increased competition in the U.S. market, leading to a 23% year-on-year decline in sales share[8] - The company’s product Posaconazole enteric-coated tablets and sustained-release bupropion hydrochloride tablets were included in the National Basic Medical Insurance Drug List, effective March 1, 2023, which is expected to enhance market accessibility[14] - The company’s Ursodeoxycholic acid capsules were selected in the eighth batch of national centralized procurement, effective July 2023, which is anticipated to boost sales growth[14] Inventory and Receivables - Accounts receivable decreased to ¥33,388,777.90 from ¥64,302,436.57, a reduction of about 48.0%[16] - Inventory increased to ¥34,621,655.40 from ¥29,376,771.68, reflecting an increase of approximately 17.3%[17] - The company reported a credit impairment loss of ¥1,619,789.58 in Q1 2023, compared to a loss of ¥606,233.66 in Q1 2022[21] Return on Equity - The return on equity (ROE) was 0.65%, a decrease of 2.18 percentage points compared to the previous year[6]

Financial Performance - The company's operating revenue for Q3 2022 was ¥59,050,376.49, a decrease of 21.29% compared to the same period last year[5] - Net profit attributable to shareholders of the listed company reached ¥23,542,682.47, a slight increase of 0.25% year-on-year[5] - Total operating revenue for the first three quarters of 2022 was CNY 186,903,609.72, a decrease of 19.1% compared to CNY 231,183,695.88 in the same period of 2021[20] - Net profit for the third quarter of 2022 was CNY 67,102,611.35, an increase of 10.4% from CNY 60,989,846.15 in the same quarter of 2021[22] - The company reported a total comprehensive income of CNY 67,293,856.17 for the third quarter of 2022, compared to CNY 60,976,227.94 in the same quarter of 2021[23] Assets and Liabilities - Total assets increased by 50.19% to ¥1,300,375,431.95 compared to the end of the previous year[6] - As of September 30, 2022, the total assets of the company amounted to RMB 1,300,375,431.95, an increase from RMB 865,805,176.29 at the end of 2021, representing a growth of approximately 50.0%[15] - The company's total liabilities decreased to RMB 150,676,111.78 from RMB 160,617,855.40, a reduction of approximately 6.0%[17] - The equity attributable to shareholders increased to RMB 453,340,000.00 from RMB 408,000,000.00, representing a growth of about 11.1%[17] - The company's equity attributable to shareholders reached CNY 1,149,699,320.17, an increase of 63.1% from CNY 705,187,320.89 in the previous year[18] Cash Flow - The net cash flow from operating activities was ¥53,938,348.13, a decrease of 6.02%[6] - The net cash flow from operating activities for the first three quarters of 2022 was CNY 53,938,348.13, compared to CNY 57,391,877.35 in the same period of 2021, reflecting a decrease of 7.9%[25] - The net cash flow from investing activities was -189,148,252.12, compared to -301,645,870.55 in the previous year, indicating an improvement[26] - Cash inflow from financing activities amounted to 389,930,139.63, while cash outflow was 13,507,380.76, resulting in a net cash flow of 376,422,758.87[26] - The overall cash increase was 245,021,205.94 compared to a decrease of 246,434,472.35 in the previous year[26] Research and Development - Research and development expenses totaled ¥16,116,208.02, down 18.09% from the previous year, representing 27.29% of operating revenue, an increase of 1.07 percentage points[6] - Research and development expenses for the first three quarters of 2022 were CNY 51,411,301.00, down 29.3% from CNY 72,799,581.02 in the previous year[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,077[10] - Major shareholder Shanghai Lianhe Investment holds 51.40% of the shares, totaling 233,000,000 shares[11] Investments - The company has a long-term investment of RMB 63,575,879.73, which increased from RMB 27,416,602.48, indicating a growth of about 132.5%[16] - The company invested 1,083,000,000.00 in cash for investments, an increase from 707,803,178.07 in the previous year[26] - The company reported a total investment cash outflow of 1,172,783,842.79, significantly higher than 718,849,773.97 from the previous year[26] Other Information - The company has not reported any new product developments or market expansion strategies in this quarter[14] - The company did not apply new accounting standards or interpretations for the year 2022[26]